Comparison Of Anti-seizure Affect Carbamazepin And Valproat Sodium In Treatment Seizure

Not Applicable

• Conditions: Condition 1: EPILEPSY. Condition 2: Seizure.; Status epilepticus; epilepsy

• Registration Number: IRCT2014050717611N1
• Lead Sponsor: Birjand University Of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 126

Inclusion Criteria

Inclusion Criteria:People with 18 years; who that not treatment with anti seizure drugs; dont have history off cva. Exclusion criteria:People with-18 years; pegnancy; cva and cerebral tumor; hysterical seizure or metabolic seizure; who that dont have change in eeg; who that dont have adhesion

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Outbreak Of Seizure. Timepoint: Start Of Treatment, Secondary week, First Month,Third Month, Fifth Month. Method of measurement: Clinical Examination, Eeg.

Secondary Outcome Measures

Name	Time	Method
Overweight. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Vomiting. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Epidermal side affect. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Headache. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Diplopia. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.;Vertigo. Timepoint: Start Of Treatment, First Month, Second Month, Fifth Month. Method of measurement: Clinical Examination.